1 Year Result 
 
2 Years Result
 
3 Years Result

2 Year Results Talent Trial

Presented @ TCT 2019, Room 213, Level 2 Moscone South. 25th Sep 2019


1Supraflex* Biodegradable polymer SES demonstrated comparable 2-year clinical outcomes to Xience EES** in all-comer population



Thin strut sirolimus-eluting stent in
All comer population
vs
Everolimus-eluting stent

R

Randomized Controlled Trial in

All Comer population 1435 patients with 1:1 randomisation

supra
vs

Xience
Family

San Francisco,USA

Dr. Azfar Zaman,presented Talent trial data at TCT 2019

C

Consistent
Performance & Lower event rates
(ITT & Per-protocol analysis)

CI-TLR=Clinically Indicated Target lesion Revascularization DOCE=Device-oriented Composite Endpoint ST=Definite or Probable Stent Thrombosis

Lower is Better

Supraflex

5.5%

Xience

7.2%

23.6 %

Lower is Better


26.6 %

Lower is Better

Supraflex

3.3%

Xience

4.5%

Supraflex

1.6%

Xience

2.3%
30.4 %

Lower is Better

C

Conclusions

  • The Supraflex* biodegradable polymer SES (sirolimus eluting stent) demonstrated comparable 2-year clinical outcome to Xience ESS** in all-comer population

Maximum Study PK Study Recoil Study Manipal Flex Study OCT Study Taxco Study Talent Flex Registry Supraflex Cruz Registry S-CORE Registry S-FLEX UK Registry
foot

  1. Talent Trial 2 Year Results presented @ TCT 2019, Room 213, Level 2 Moscone South. 25th Sep 2019. San Francisco, USA
 *Supraflex is trademark of Sahajanand Medical Technologies Pvt. Ltd. or its addiliates.  
**XIENCE is trademark of the Abbott Group of Companies.
SMT © 2019 | All Rights Reserved